Table 1 Clinical and Treatment Characteristics
Characteristics | Sorafenib group (n = 275) | Control group (n = 338) | P |
|---|---|---|---|
Sex, male/female (n%) | 143 (53%)/132 (47%) | 176 (52%)/162 (48%) | 0.86 |
Age, median (IQR), years | 36 (26–45) | 37 (27–47) | 0.24 |
WBC count at diagnosis, median (IQR) | 53.1 (15.7–119.5) | 52.9 (12.9–118.5) | 0.96 |
Cycles of chemotherapy pre-transplant, median (IQR) | 3 (3–4) | 3 (3–4) | 0.73 |
Initial induction regimens | 0.25 | ||
Anthracyclines plus cytarabine | 256 (93%) | 306 (91%) | |
Others | 19 (7%) | 32 (9%) | |
Cytogenetics risk stratification (n%) | 0.90 | ||
Favorable | 20 (7%) | 26 (8%) | |
Intermediate | 229 (83%) | 279 (83%) | |
Adverse | 26 (9%) | 33 (10%) | |
2017 ELN risk stratification (n%) | 0.90 | ||
Favorable | 77 (28%) | 83 (25%) | |
Intermediate | 84 (31%) | 75 (22%) | |
Adverse | 83 (30%) | 103 (30%) | |
Unknown | 31 (11%) | 77 (23%) | |
Disease status at transplant (n%) | 0.79 | ||
CRc | 238 (87%) | 287 (85%) | |
PR | 10 (4%) | 16 (5%) | |
NR | 27 (10%) | 35 (10%) | |
Sorafenib pre-transplant (n%) | 0.028 | ||
Use | 149 (54%) | 153 (45%) | |
No use | 126 (46%) | 185 (55%) | |
Transplant modality (n%) | 0.99 | ||
MSD | 112 (41%) | 139 (41%) | |
MUD | 22 (8%) | 20 (6%) | |
HID | 141 (51%) | 179 (53%) |
